panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT03442569
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
- Conditions
- Interventions
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT03366155
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Hellenic Cooperative Oncology Group
- Target Recruit Count
- 23
- Registration Number
- NCT03311750
- Locations
- 🇬🇷
University Hospital of Heraklion, Heraklion, Crete, Greece
🇨🇾Bank Of Cyprus Oncology Centre, Strovolos, Nicosia, Cyprus
🇬🇷Agii Anargiri Cancer Hospital, Athens, Kalyftaki, Nea Kifisia, Greece
First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 435
- Registration Number
- NCT03231722
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Oncologico Veneto, Padova, Italy
🇮🇹A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica, Pisa, Italy
🇮🇹Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 132
- Registration Number
- NCT03186326
- Locations
- 🇫🇷
Ch - Centre Hospitalier Intercommunal, Villeneuve-Saint-Georges, France
🇫🇷Ch - Centre Hospitalier Du Pays D'Aix, Aix-en-Provence, France
🇫🇷Privé - Institut Sainte Catherine, Avignon CEDEX, France
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
- Conditions
- Interventions
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2021-06-21
- Target Recruit Count
- 20
- Registration Number
- NCT03142516
- Locations
- 🇪🇸
Hospital Sant Joan Despí-Moises Broggi, Sant Joan Despí, Barcelona, Spain
🇪🇸ICO L´Hospitalet de Llobregat - Hospital Durán i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Universitario la Paz, Madrid, Spain
Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT03069950
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memoral Sloan Kettering Westchester, Harrison, New York, United States
Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 647
- Registration Number
- NCT03043950
- Locations
- 🇩🇪
Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Baden-Württemberg, Germany
Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2022-03-17
- Target Recruit Count
- 34
- Registration Number
- NCT03000374
- Locations
- 🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital de Sant Joan Despí Moisés Broggi, Sant Joan Despí, Barcelona, Spain
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.